Viking Therapeutics, Inc.
VKTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $4,388 | $1,756 | $722 | $355 |
| - Cash | $27 | $56 | $37 | $26 |
| + Debt | $1 | $1 | $2 | $0 |
| Enterprise Value | $4,362 | $1,702 | $687 | $329 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$151 | -$101 | -$70 | -$55 |
| % Margin | – | – | – | – |
| Net Income | -$110 | -$86 | -$69 | -$55 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.01 | -0.91 | -0.88 | -0.7 |
| % Growth | -11% | -3.4% | -25.7% | – |
| Operating Cash Flow | -$88 | -$73 | -$48 | -$48 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$88 | -$73 | -$48 | -$48 |